Pharming Group (NASDAQ:PHAR – Get Free Report) and Invivyd (NASDAQ:IVVD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.
Volatility & Risk
Pharming Group has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
Profitability
This table compares Pharming Group and Invivyd’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pharming Group | 6.23% | 8.70% | 4.93% |
| Invivyd | -183.90% | -59.73% | -48.97% |
Insider and Institutional Ownership
0.0% of Pharming Group shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 12.2% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Pharming Group and Invivyd, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pharming Group | 0 | 2 | 3 | 0 | 2.60 |
| Invivyd | 1 | 1 | 3 | 0 | 2.40 |
Pharming Group presently has a consensus target price of $39.67, indicating a potential upside of 214.81%. Invivyd has a consensus target price of $10.00, indicating a potential upside of 1,617.92%. Given Invivyd’s higher possible upside, analysts clearly believe Invivyd is more favorable than Pharming Group.
Earnings & Valuation
This table compares Pharming Group and Invivyd”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pharming Group | $376.13 million | 2.37 | $2.85 million | $0.32 | 39.38 |
| Invivyd | $53.43 million | 3.21 | -$52.49 million | ($0.33) | -1.76 |
Pharming Group has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Summary
Pharming Group beats Invivyd on 8 of the 13 factors compared between the two stocks.
About Pharming Group
Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
About Invivyd
Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
